| Code | CSB-RA011661MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Stapokibart, targeting the interleukin-4 receptor (IL4R), a type I transmembrane protein critical for mediating signaling of both IL-4 and IL-13 cytokines. IL4R plays a central role in type 2 immune responses by promoting Th2 cell differentiation, IgE class switching in B cells, and alternative macrophage activation. Dysregulated IL4R signaling is implicated in various allergic and inflammatory conditions, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis, making it an important therapeutic target for type 2 inflammatory diseases.
Stapokibart is a clinical-stage therapeutic antibody that blocks IL4R alpha subunit, thereby inhibiting both IL-4 and IL-13 signaling pathways. This biosimilar antibody provides researchers with a valuable tool for investigating IL4R-mediated immune mechanisms, studying type 2 inflammation pathways, and exploring potential therapeutic interventions in allergic and inflammatory disease models. It supports various research applications in immunology, inflammation biology, and therapeutic antibody development.
There are currently no reviews for this product.